Universal aspirin administration (162 mg daily) starting early in pregnancy reduces incidence and delays onset of preeclampsia with severe features in high-risk populations.
Implementation of direct aspirin dispensation during prenatal visits leads to high adherence (~80%) and favorable maternal and neonatal outcomes without increased bleeding or abruption risk.
Early aspirin initiation (before 12 weeks’ gestation) further improves hypertensive and neonatal outcomes beyond standard practice.
Advanced first-trimester screening algorithms incorporating biomarkers (e.g., PlGF) enhance risk identification but may benefit from complementing universal aspirin strategies in high-prevalence settings.
